Background-Optimal platelet inhibition is an important therapeutic adjunct in patients acute myocardial infarction (AMI) undergoing coronary stenting. Whether adjunctive cilostazol to dual antiplatelet therapy (triple antiplatelet therapy) can inhibit enhanced platelet reactivity in patients with AMI yet has not been determined. The aim of this study was to assess the degree of platelet inhibition by triple antiplatelet therapy in patients with AMI. Methods and Results-Immediately after emergency room arrival, patients with AMI received clopidogrel (600-mg loading dose, followed by 75 mg daily) and aspirin (300-mg loading dose and 200 mg daily throughout the study period). After patients underwent coronary stenting (nϭ90), they were randomly assigned to 1 of 3 groups before discharge: standard group, clopidogrel of 75 mg daily (nϭ30); high maintenance dose (MD) group, clopidogrel of 150 mg daily (nϭ30); and triple group, adjunctive cilostazol of 100 mg twice daily to clopidogrel of 75 mg daily (nϭ30). Platelet reactivity was assessed at predischarge and 30-day follow-up by conventional aggregometry and the VerifyNow P2Y12 assay. Predischarge platelet reactivities were similar in the 3 groups. At 30-day follow-up, inhibition of maximal aggregation with 20 M ADP stimuli was 6.0% in the standard group, 19.1% in the high-MD group, and 42.4% in the triple group (PϽ0.001), whereas inhibition of late aggregation with 20M ADP stimuli was 10.8%, 38.1%, and 66.4%, respectively (PϽ0.001). Similar results were demonstrated when 5 M ADP was used. Furthermore, percent changes of P2Y12 reaction unit were significantly different among regimens (10.6% in the standard group, 30.7% in the high-MD group, and 43.0% in the triple group; PϽ0.001). With respect to high-postclopidogrel platelet reactivity (prespecified as 20 M ADP-induced maximal aggregation Ͼ50% of light transmission), fewer patients in the triple group (13.3%) met the criteria as compared with those in the standard (76.7%) and high-MD groups (56.7%) at 30-day follow-up (PϽ0.001). In the triple group, there were more potent and consistent platelet inhibitions by all parameters as compared with the high-MD group except for percent changes of P2Y12 reaction unit (Pϭ0.071). Conclusions-Among patients with AMI undergoing coronary stenting, triple antiplatelet therapy results in a greater antiplatelet effect at 30 days as compared with a high-MD clopidogrel or standard dual antiplatelet therapy. (Circ Cardiovasc Interv. 2010;3:17-26.)
phase of AMI. 5, 6 In recent studies, high-postclopidogrel platelet reactivity (HPPR) in patients with AMI has been associated with ischemic clinical events including stent thrombosis, [7] [8] [9] which together with the observation that prasugrel through its potent blockade of the P2Y12 ADP receptor reduces the occurrence of ischemic events after AMI, suggests a need to achieve adequate inhibition of ADP-induced platelet aggregation in patients with AMI. 10, 11 Although compared with dual antiplatelet therapy, adjunctive cilostazol to dual antiplatelet therapy (or "triple antiplatelet therapy") reduces long-term clinical events after PCI in selected patient populations, 12, 13 it has not been established whether the benefit of triple antiplatelet therapy may be derived from greater ADP-induced platelet inhibition in patients with AMI. Therefore, we conducted a prospective, randomized study to ascertain the degree of platelet inhibition by adjunctive cilostazol in patients with AMI.
Methods

Patient Population and Study Design
Consecutive patients admitted for AMI were enrolled if they were 18 years or older and had undergone successful coronary stenting. We defined AMI as clinical symptoms compatible with acute myocardial ischemia within 12 hours before admission with a subsequently documented increase in cardiac troponin levels. ST-segment-elevation myocardial infarction was prespecified as ST-segment elevation Ն1 mm in at least 2 contiguous leads in the admission ECG or left bundle-branch block, and all patients with ST-segment-elevation myocardial infarction were treated with primary stenting Ͻ12 hours after the onset of pain. The remaining patients with AMI with no such ECG changes constituted the non-ST-segment-elevation myocardial infarction cohort, and all patients with non-ST-segment-elevation myocardial infarction underwent coronary stenting within 24 hours after admission. Exclusion criteria for the study were a history of active bleeding and bleeding diatheses, oral anticoagulation therapy with coumadin, left ventricular ejection fraction Ͻ30%, leukocyte count Ͻ3000/mm 3 and/or platelet count Ͻ100 000/mm 3 , aspartate aminotransferase (AST) or alanine aminotransferase (ALT) level Ն3 times the respective upper normal limits, serum creatinine level Ն2.5 mg/dL, or noncardiac disease with a life expectancy Ͻ1 year. The institutional review board of Gyeongsang National University Hospital approved the study protocol, and all patients signed written informed consents for participation.
The adjunctive cilostazol versus high maintenance dose (MD) clopidogrel in patients with AMI (ACCEL-AMI) study is a prospective, randomized study including 90 patients with AMI undergoing coronary stenting (Figure 1 ). This study has no overlap in terms of enrolled patients with the adjunctive cilostazol versus high-MD clopidogrel in patients with clopidogrel RESISTANCE (ACCEL-RESISTANCE) study, which enrolled patients treated with elective PCI. 14 Immediately after emergency room arrival, all patients received a 600-mg loading dose of clopidogrel followed by a MD of 75 mg daily before randomization. We also administered a 300-mg loading dose of aspirin to all patients immediately after emergency room arrival, followed by aspirin of 200 mg daily throughout the study period. Low-molecular-weight heparin (enoxaparin) or unfractionated heparin was used at the physician's discretion before PCI, and only the short half-life GPIIb/IIIa inhibitor tirofiban was administered if needed. Predischarge platelet reactivity was assessed either at least 3 days after coronary stenting in patients not treated with tirofiban or at Ն5 days after procedure in patients treated with tirofiban. After blood sampling, patients were randomly assigned in a 1:1:1 ratio to 1 of 3 groups using a computer-generated randomization sequence: standard group (nϭ30), clopidogrel of 75 mg daily; high-MD group (nϭ30), clopidogrel of 150 mg daily; and triple group (nϭ30), adjunctive cilostazol of 100 mg twice daily to clopidogrel of 75 mg daily. At the 30-day follow-up visit, patient compliance to antiplatelet therapy was assessed by interview and tablet counting. Blood samples were obtained 2 to 4 hours after the last intake of the study medication.
Platelet Function Assays
Light transmittance aggregometry and the VerifyNow P2Y12 assay (Ultegra rapid platelet function assay; Accumetrics, San Diego, Calif) were performed as previously described. 14 To perform light transmittance aggregometry, blood samples were drawn into Vacutainer tubes containing 0.5 mL of sodium citrate 3.2% (BectonDickinson, San Jose, Calif) and processed within 2 hours. Plateletrich plasma was obtained as a supernatant fluid after centrifuging blood at 120 g for 10 minutes. The remaining blood was further centrifuged at 1200 g for 10 minutes to prepare platelet-poor plasma. Platelet-rich plasma was adjusted to a platelet count of 250 000/mm 3 by adding platelet-poor plasma as needed. Platelet reactivity was traced for 10 minutes at 37°C using an AggRAM aggregometer (Helena Laboratories Corp, Beaumont, Tex) ( Figure 2 ). Light transmission was adjusted to 0% with platelet-rich plasma and to 100% with platelet-poor plasma for each measurement. The 5 and 20 M ADP-induced platelet aggregations were determined at maximal aggregation (Agg max ) and late aggregation at 5 minutes (Agg late ) by laboratory personnel blinded to the study protocol. Inhibition of platelet aggregation was defined as relative change of aggregation values between predischarge and 30-day followup: inhibition of platelet aggregation (%) ϭ ([predischarge platelet reactivityϪplatelet reactivity at 30- 15 The results of the VerifyNow P2Y12 assay were reported in P2Y12 reaction unit (PRU) and % platelet inhibition. Percent change of PRU was calculated as the relative change of PRU between predischarge and 30-day follow-up: percent change of PRU (%)ϭ([predischarge PRUϪPRU at 30-day follow-up]/[predischarge PRU])ϫ100. 14 
End Points and Definitions
Primary end points were inhibitions of Agg max between predischarge and 30-day follow-up. Secondary end points were (1) inhibitions of Agg late ; (2) percent changes of PRU; (3) percentage of platelet disaggregation; and (4) the rate of HPPR. The cutoff point of HPPR was defined as 5 or 20 M ADP-induced Agg max Ͼ50% of light transmission. 15, 16 In addition, we assessed the composite of death, MI, urgent target-vessel revascularization, or stent thrombosis at 30-day follow- 
Sample Size Calculation and Statistical Analysis
Based on previous studies, 15, 17 we assumed a 22% increase in inhibition of 20 M ADP-induced Agg max by high-MD clopidogrel and a 47% increase in inhibition of 20 M ADP-induced Agg max by triple antiplatelet therapy, relative to those by dual antiplatelet therapy. Thus, it was estimated that 25 patients per group would be required to provide a power of 80% to detect a statistically significant difference between the triple and high-MD groups with a 2-sided ␣-level of 0.05, assuming a SD of 30%. Continuous variables are expressed as meanϮSD or median (interquartile range), and their differences were tested with 1-way ANOVA. After demonstration of significant differences among groups by ANOVA, posthoc comparisons between group pairs were made with the Student-Newman-Keuls procedure for multiple comparisons. Categorical variables are expressed as frequencies and percentages, and 2 statistics or Fisher exact test was used for their comparisons. Statistical analyses were performed using SPSS version 13 (SPSS Inc, Chicago, Ill) and conducted at the 0.05 significance level.
Results
When baseline characteristics of patients were compared among the 3 groups, no significant differences were noted in any of the parameters (Table 1) . Patients were treated with drug-eluting stent implantation only. Predischarge values of light transmittance aggregometry and the VerifyNow P2Y12 assay were similar among the groups (Tables 2 and 3 ). There were no significant differences between patients with non-ST-segment-elevation myocardial infarction and ST-segment-elevation myocardial infarction among the 3 groups (supplemental Tables). Although there were 3 cases of transient headache in the triple group in the early phase after randomization, all regimens were generally well tolerated during 30 days. No patients discontinued the study regimens, and platelet function measurements at 30-day follow-up could be performed in all patients. No major cardiovascular and bleeding events were observed in any group, and the incidence of minor bleeding was similar in the 3 groups (3% in the standard group versus 0% in the high-MD group versus 3% in the triple group, Pϭ1.000).
Primary End Points
Agg max values at 30-day follow-up in the triple group were significantly lower as compared with those in the other 2 therapy groups (Table 2) . After any of the tested concentrations of ADP stimuli, inhibitions of Agg max were consistently greater in the triple group as compared with the other groups (Figure 3) . Inhibition of Agg max with 5 Values are expressed as meanϮSD or n (%). BMI indicates body mass index; STEMI, ST-segment-elevation myocardial infarction; NSTEMI, non-ST-segment-elevation myocardial infarction; MI, myocardial infarction; CABG, coronary artery bypass grafting; CYP 3A4, cytochrome P-450 3A4 isoenzyme; ACE, angiotensin-converting enzyme; ARB, angiotensin receptor blocker; LV, left ventricular; Hb A1 C , hemoglobin A1 C ; TIMI, thrombolysis in myocardial infarction; GPI, glycoprotein IIb/IIIa inhibitor.
M ADP stimuli was 49.2Ϯ19.9% in the triple group, 23.9Ϯ20.3% in the high-MD group, and 6.9Ϯ20.8% in the standard group (PϽ0.001), whereas it was 42.4Ϯ21.1%, 19.1Ϯ18.6%, and 6.0Ϯ13.1% with 20 M ADP stimuli, respectively (PϽ0.001).
Secondary End Points
Agg late values at 30-day follow-up were also significantly reduced in the triple group as compared with the other 2 groups ( Table 2) . Inhibitions of Agg late in the triple group were consistently higher than those in the other groups ( Figure 4A ). Inhibitions of Agg late after the addition of 5 M ADP were 70.8Ϯ26.4% in the triple group, 40.1Ϯ30.7% in the high-MD group, and 16.6Ϯ43.0% in the standard group (PϽ0.001), and inhibitions of Agg late after the addition of 20 M ADP were 66.4Ϯ34.3%, 38.1Ϯ41.7%, and 10.8Ϯ35.7%, respectively (PϽ0.001).
At 30-day follow-up, the triple group presented trends toward lower PRU and higher % platelet inhibition as compared with the high-MD group (Table 3) . Percent changes of PRU significantly differed according to the regimens (10.6Ϯ23.1% in the standard group versus 30.7Ϯ27.5% in the high-MD group versus 43.0Ϯ24.4% in the triple group, PϽ0.001) ( Figure 4B ). Triple antiplatelet therapy enhanced percent change of PRU with a greater numeric difference than that of high-MD clopidogrel (Pϭ0.071).
Platelet disaggregation at predischarge was similar among the groups with 5 M (22.7Ϯ20.9% in the standard group versus 24.1Ϯ21.2% in the high-MD group versus 21.3Ϯ17.6% in the triple group, Pϭ0.863) and 20 M ADP stimuli (17.7Ϯ18.1% in the standard group versus 18.3Ϯ22.5% in the high-MD group versus 16.4Ϯ14.0% in the triple group, Pϭ0.920). Thirty days after randomization, patients enrolled to all groups experienced an increase in platelet disaggregation; however, enhanced platelet disaggregation was observed in patients assigned to the triple group versus the other 2 groups ( Figure 4C ). In terms of HPPR, no between-group differences were seen at predischarge after stimuli with either of the ADP concentrations tested ( Figure 5A and 5B). At 30-day follow-up, triple antiplatelet therapy significantly reduced the rate of HPPR as compared with the other antiplatelet therapies after addition of 5 M (26.7% in the standard group versus 16.7% in the high-MD group versus 0% in the triple group, PϽ0.001) and 20 M ADP (76.7% in the standard group versus 56.7% in the high-MD group versus 13.3% in the triple group, PϽ0.001).
Discussion
This study shows enhanced inhibition of ADP-induced platelet aggregation by adjunctive cilostazol to dual antiplatelet therapy in patients with AMI undergoing coronary stenting. The salient finding of this study is that triple antiplatelet therapy may result in a greater antiplatelet effect than a high-MD clopidogrel of 150 mg daily in patients with AMI. Furthermore, triple antiplatelet therapy reduced significantly the rate of HPPR as compared with high-MD clopidogrel, which may underlie the reduced rates of ischemic events with adjunctive cilostazol.
Most cases of AMI are caused by the formation of a platelet-rich arterial thrombus at the site of atherosclerotic plaque rupture or erosion, and PCI in patients with AMI may predispose to thrombotic events because of enhanced platelet reactivity and large thrombotic burden. 5, 6 P2Y12 blockade by a standard dose of clopidogrel demonstrates variable ADP-induced platelet inhibition in patients with AMI. Furthermore, a lesser inhibition of platelet reactivity by clopidogrel has been associated with a higher risk of ischemic events including stent thrombosis. [7] [8] [9] [10] In patients with non-ST-segment-elevation (NSTE) acute coronary syndrome, a 600-mg loading dose of clopidogrel showed greater inhibition of platelet reactivity and better clinical outcomes compared with a 300-mg loading dose of clopidogrel. 18 Prasugrel has a greater inhibitory effect on ADP-induced platelet aggregation than high-MD clopidogrel. 19 Prasugrel also significantly reduces ischemic event rates by 19% as compared with a standard clopidogrel dose (hazard ratio, 0.81; 95% CI, 0.73 to 0.90; PϽ0.001) in patients with acute coronary syndrome. 10, 11, 20 These results suggest the hypothesis that a standard dose of clopidogrel may be inadequate to inhibit enhanced platelet reactivity in the case of acute coronary syndrome, and greater ADP-induced platelet inhibition in these patients may result in greater suppression of clinical ischemic events.
Recent data demonstrated that triple antiplatelet therapy may be better than dual antiplatelet therapy in reducing long-term ischemic event occurrence in patients with acute coronary syndrome undergoing coronary stenting. 12, 13 Cilostazol is a selective inhibitor of phosphodiesterase type III in both platelets and vascular smooth muscle cells. 21 Clinical benefit of adjunctive cilostazol to standard antiplatelet therapy in patients with AMI might be related to a myocardial protective effect against ischemiareperfusion injury, 22 restoration of endothelial dysfunction, 23, 24 or reduction of in-stent restenosis. [25] [26] [27] However, a main impact of adjunctive cilostazol to clopidogrel in patients with AMI may come from enhanced inhibition of ADP-induced platelet aggregation. 14, 17, 28 This phenomenon may be elucidated by a supplementary elevation of intracellular cAMP through both increase of cAMP production by clopidogrel and inhibition of cAMP degradation by cilostazol. 28 Moreover, this study showed that triple antiplatelet therapy may result in greater ADPinduced platelet inhibition than a high-MD clopidogrel of 150 mg daily in patients with AMI. If triple antiplatelet therapy achieves the optimal balance between adequate platelet inhibition and acceptable adverse effect rates, it could be a welcome option for patients with AMI.
In this study, the standard group showed a low relative change of platelet aggregation between predischarge and 30-day follow-up. Although patients with AMI may show enhanced platelet reactivity during the early phase, the impact of increased platelet reactivity may not be much higher than those of other clinical factors. 29, 30 Thus, inhibition of platelet aggregation in this study may be within the acceptable range. Enhanced platelet inhibition with high-MD clopidogrel may be somewhat lower compared with those of previous studies. 15, 31 We enrolled patients who presented with AMI only, contrary to previous studies including patients on chronic clopidogrel therapy (Ն1 month). There might be a dynamic change of platelet reactivity in the early phase of AMI, and it could affect the postclopidogrel platelet inhibition seen in our patients. In addition, ethnic differences may be related with the reduced response to high-MD clopidogrel. Carriers with the cytochrome P450 (CYP) 2C19 mutant allele have shown reduced platelet inhibition with clopidogrel and a higher rate of major adverse cardiovascular events, than did noncarriers. 32, 33 Because the common polymorphism of the CYP2C19 gene is more prominent among East Asians than whites (Ϸ60% versus 30%), [32] [33] [34] additive platelet inhibition with high-MD clopidogrel would be much diminished in East Asians. Furthermore, cilostazol is mainly converted into active metabolites by the CYP3A system, 35 which translates into less impact of the CYP2C19 mutant allele for additive platelet inhibition with cilostazol. Further large-scale studies assessing whether intensified antiplatelet therapy in patients with AMI provides similar efficacy of ADP-induced platelet inhibition according to ethnicity are needed.
Limitations
The small number of patients studied and the short follow-up period are limitations of this study. Patients with AMI show enhanced platelet reactivity during the early phase, and their platelet reactivity can be decreased thereafter. Measurements of the standard group may provide a reference for decreasing platelet reactivity after AMI. Because this study enrolled East Asians only, results cannot be generalized to a global scale. One major limitation of this study may be the time point of platelet function measurements. Matetzky et al 7 showed that there may be no significant changes of postclopidogrel platelet reactivity from days 3 to 5 after coronary stenting in patients with AMI. Because we assessed platelet reactivity mostly from 3 to 5 days after coronary stenting, the results from our patients may principally reflect predischarge residual platelet reactivity.
Conclusions
Among patients with AMI undergoing coronary stenting, triple antiplatelet therapy results in a greater antiplatelet effect than a high-MD clopidogrel of 150 mg daily. The use of triple antiplatelet therapy in patients with AMI may achieve adequate inhibition of ADP-induced platelet aggregation to suppress the occurrence of major adverse cardiovascular events.
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